title: Effectiveness of switching between biologics in psoriatic arthritis- results of a large regional survey.
authors.affiliation: Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
authors.forename: Meghna
authors.initials: M
authors.lastname: Jani
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Macphie
authors.forename: Chandani
authors.initials: C
authors.lastname: Rao
authors.forename: Sarah
authors.initials: S
authors.lastname: Moore
authors.forename: Hoda
authors.initials: H
authors.lastname: Mirjafari
authors.forename: Yokemie
authors.initials: Y
authors.lastname: McLoughlin
authors.forename: Hector
authors.initials: H
authors.lastname: Chinoy
authors.forename: Preeti
authors.initials: P
authors.lastname: Shah
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D000068800:Etanercept; D005260:Female; D019983:Guideline Adherence; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D017211:Treatment Failure; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D006113:United Kingdom
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; C529000:golimumab; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept